Antoine Thiery-Vuillemin

10.0k total citations · 2 hit papers
155 papers, 3.7k citations indexed

About

Antoine Thiery-Vuillemin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Antoine Thiery-Vuillemin has authored 155 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Pulmonary and Respiratory Medicine, 85 papers in Oncology and 33 papers in Cancer Research. Recurrent topics in Antoine Thiery-Vuillemin's work include Prostate Cancer Treatment and Research (57 papers), Renal cell carcinoma treatment (46 papers) and PARP inhibition in cancer therapy (26 papers). Antoine Thiery-Vuillemin is often cited by papers focused on Prostate Cancer Treatment and Research (57 papers), Renal cell carcinoma treatment (46 papers) and PARP inhibition in cancer therapy (26 papers). Antoine Thiery-Vuillemin collaborates with scholars based in France, United States and United Kingdom. Antoine Thiery-Vuillemin's co-authors include Fred Saad, Karim Fizazi, Oliver Sartor, Jinyu Kang, Joaquı́n Mateo, Johann S. de Bono, Neeraj Agarwal, David Olmos, Neal D. Shore and Carrie A. Adelman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Antoine Thiery-Vuillemin

143 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020 1.4k citations Johann S. de Bono, Joaquı́n Mateo et al. New England Journal of Medicine profile →
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

2020 474 citations Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Antoine Thiery-Vuillemin

Since Specialization

Citations

This map shows the geographic impact of Antoine Thiery-Vuillemin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoine Thiery-Vuillemin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoine Thiery-Vuillemin more than expected).

Fields of papers citing papers by Antoine Thiery-Vuillemin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoine Thiery-Vuillemin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoine Thiery-Vuillemin. The network helps show where Antoine Thiery-Vuillemin may publish in the future.

Co-authorship network of co-authors of Antoine Thiery-Vuillemin

This figure shows the co-authorship network connecting the top 25 collaborators of Antoine Thiery-Vuillemin. A scholar is included among the top collaborators of Antoine Thiery-Vuillemin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoine Thiery-Vuillemin. Antoine Thiery-Vuillemin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of cancer treatments in hemodialysis patients 2023 ·Bulletin du Cancer ·(unknown), Kévin Bihan, Corinne Isnard Bagnis, Noël Zahr, Antoine Thiery-Vuillemin, Paul Gougis, Luca Campedel	2
2	Evaluation of local control after percutaneous microwave ablation versus partial nephrectomy: A propensity score matched study 2023 ·PubMed ·(unknown), (unknown), A. David, Antoine Thiery-Vuillemin, F. Kleinclauss, (unknown)	4
3	PO-1479 Management of androgen deprivation therapy (ADT) by French radiation oncologists, TALISMAN study 2023 ·Radiotherapy and Oncology ·G. Créhange, Thierry Lebrét, Antoine Thiery-Vuillemin, (unknown), Valérie Perrot, J. Rigaud	0
4	1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial 2023 ·Annals of Oncology ·Stéphane Oudard, Raffaele Ratta, Éric Voog, Philippe Barthélémy, Antoine Thiery-Vuillemin, Mostefa Bennamoun, Ali Hasbini, (unknown), (unknown), Gunhild von Amsberg, Nadine Houédé, (unknown), Susan Feyerabend, Martin Boegemann, Alexandre Falcoz, Déwi Vernerey, (unknown), Salma Kotti, (unknown), Carole Hélissey	1
5	Detection of BRCA1 , BRCA2 , and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound 2022 ·Clinical Cancer Research ·Kim N., Alan Barnicle, (unknown), Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann S. de Bono, Joaquı́n Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington	46
6	1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial 2022 ·Annals of Oncology ·Andrew J. Armstrong, (unknown), Antoine Thiery-Vuillemin, (unknown), Neal D. Shore, (unknown), Mustafa Özgüroğlu, Craig Gedye, Oliver Sartor, Christian Poehlein, (unknown), YZ Liu, Laura Riva, (unknown), Laura Barker, Paula Michelle del Rosario, Alan Barnicle, (unknown)	6
7	LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1 2021 ·Annals of Oncology ·Karim Fizazi, Joan Carles, (unknown), Guilhem Roubaud, Ray McDermott, Aude Fléchon, Bertrand Tombal, S. Supiot, Dominik Berthold, Philippe Ronchin, Gabriel Kacsó, Gwénaëlle Gravis, Fabio Calabrò, Jean François Berdah, Ali Hasbini, (unknown), Antoine Thiery-Vuillemin, I. Latorzeff, Isabelle Rieger, Alberto Bossi	31
8	Olaparib for Metastatic Castration-Resistant Prostate Cancer breakdown → 2020 ·New England Journal of Medicine ·Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain	1397
9	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer breakdown → 2020 ·New England Journal of Medicine ·Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Claire Corcoran, Carrie A. Adelman, Johann S. de Bono	474
10	722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study 2020 ·Annals of Oncology ·Marine Gross‐Goupil, Aude Fléchon, Loı̈c Mourey, Delphine Topart, Gwénaëlle Gravis, Stéphane Oudard, J.M. Tourani, Lionnel Geoffrois, (unknown), Antoine Thiery-Vuillemin, Philippe Barthélémy, Sylvain Ladoire, Brigitte Laguerre, (unknown), Valérie Perrot, Bernard Escudier, Laurence Albigès	4
11	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study 2020 ·European Journal of Cancer ·(unknown), Marine Gross‐Goupil, Valérie Seegers, (unknown), Benoit Beuselinck, Constance Thibault, Christine Chevreau, Sylvain Ladoire, Philippe Barthélémy, Sylvie Négrier, Delphine Borchiellini, Olivier Huillard, Lionnel Geoffrois, Gwénaëlle Gravis, (unknown), Antoine Thiery-Vuillemin, Bernard Escudier, Alain Ravaud, Laurence Albigès	20
12	Effets secondaires de la chimiothérapie des cancers testiculaires et suivi de l’après cancer 2019 ·Bulletin du Cancer ·Florence Joly, (unknown), Antoine Thiery-Vuillemin, (unknown), Elodie Coquan	5
13	Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial 2016 ·Medical Oncology ·Fabien Calcagno, Guillaume Mouillet, Olivier Adotévi, Tristan Maurina, Thierry Nguyen, Philippe Montcuquet, Elsa Curtit, F. Kleinclauss, Xavier Pivot, Christophe Borg, Antoine Thiery-Vuillemin	7
14	In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy? 2015 ·The Oncologist ·Xavier Pivot, Laura Mansi, L. Chaigneau, Philippe Montcuquet, Antoine Thiery-Vuillemin, Fernando Bazán, Erion Dobi, (unknown), (unknown), (unknown), (unknown), Farid Jamshidian, Phillip G. Febbo, Christer Svedman, Sophie Paget‐Bailly, Franck Bonnetain, (unknown)	19
15	Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06 2013 ·Targeted Oncology ·(unknown), Gilles Romieu, J Salvat, L. Chaigneau, Yacine Merrouche, Trang Huyen Thi Nguyen, Antoine Thiery-Vuillemin, Martin Demarchi, Erion Dobi, Xavier Pivot	9
16	Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer 2012 ·Clinical Colorectal Cancer ·Erion Dobi, Franck Monnien, Stéfano Kim, (unknown), (unknown), Martin Demarchi, Olivier Adotévi, Antoine Thiery-Vuillemin, (unknown), B Kantelip, Xavier Pivot, Yann Godet, (unknown), Christophe Borg	34
17	Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells 2011 ·Cancer Research ·Romain Bedel, Antoine Thiery-Vuillemin, Camille Grandclément, Jérémy Balland, Jean-Paul Rémy-Martin, B Kantelip, Jean‐René Pallandre, Xavier Pivot, Christophe Ferrand, Pierre Tiberghien, Christophe Borg	94
18	Combining molecular targeted therapies 2011 ·Anti-Cancer Drugs ·Xavier Pivot, (unknown), Antoine Thiery-Vuillemin, Marc Espié, Michel Marty	7
19	Sequential taxane and anthracycline-containing neoadjuvant regimens: The sequential order impact 2010 ·The Breast ·Antoine Thiery-Vuillemin, Antonio Llombart‐Cussac, L. Chaigneau, Cristian Villanueva, Fernando Bazán, Philippe Montcuquet, (unknown), (unknown), (unknown), Xavier Pivot	7
20	Anticancer therapy in patients with porphyrias: evidence today 2008 ·Expert Opinion on Drug Safety ·Antoine Thiery-Vuillemin, L. Chaigneau, N. Méaux-Ruault, Cristian Villanueva, Thierry Nguyen, Tristan Maurina, Ulrich Stein, Véronique Lorgis, Martin Demarchi, Xavier Pivot	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact